UNODC. World Drug Report 2016. United Nations 2016.
Cruickshank CC, Dyer KR. A review of the clinical pharmacology of methamphetamine. Addiction. 2009;104(7):1085–99.
Hadamitzky M, Mccunney S, Markou A, Kuczenski R. Development of stereotyped behaviors during prolonged escalation of methamphetamine self-administration in rats. Psychopharmacology. 2012;223(3):259–69.
Pritchard LM, Hensleigh E, Lynch S. Altered locomotor and stereotyped responses to acute methamphetamine in adolescent, maternally separated rats. Psychopharmacology. 2012;223(1):27–35.
Kita T, Miyazaki I, Asanuma M, Takeshima M, Wagner GC. Chapter 3 - dopamine-induced behavioral changes and oxidative stress in methamphetamine-induced neurotoxicity. International Rev of Neurobiology. 2009;88(88):43–64.
Cho AK, Melega WP. Patterns of methamphetamine abuse and their consequences. J Addictive Dis. 2002;21(1):21–34.
Kitamura O, Tokunaga I, Gotohda T, S-i K. Immunohistochemical investigation of dopaminergic terminal markers and caspase-3 activation in the striatum of human methamphetamine users. International J Leg Med. 2007;121(3):163–8.
UD MC, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [C-11]WIN-35,428. J Neuroscience. 1998;18(20):8417–22.
Volkow ND, Chang L, Wang GJ, Fowler JS, Franceschi D, Sedler M, et al. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neuroscience. 2001;21(23):9414–8.
Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, et al. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med. 1996;2(6):699–703.
Volkow ND, Fowler JS, Wang GJ, Swanson JM. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry. 2004;9(6):557–69.
McCann UD, Kuwabara H, Kumar A, Palermo M, Abbey R, Brasic J, et al. Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users. Synapse. 2008;62(2):91–100.
Courtney KE, Ray LA. Methamphetamine: an update on epidemiology, pharmacology, clinical phenomenology, and treatment literature. Drug Alcohol Dependence. 2014;143:11–21.
Cao D-N, Shi J-J, Hao W, Wu N, Li J. Advances and challenges in pharmacotherapeutics for amphetamine-type stimulants addiction. European J Pharmacology. 2016;780:129–35.
Min X, Lee D-T, Jinhua X, Wenjun D, Li C, Bin D, et al. A database on treating drug addiction with traditional chinese medicine. Addiction. 2007;102(2):282–8.
Wang S, Liu L, Wang L, Hu Y, Zhang W, Liu R. Structural characterization and identification of major constituents in Jitai tablets by high-performance liquid chromatography/diode-Array detection coupled with electrospray ionization tandem mass spectrometry. Molecules. 2012;17(9):10470–93.
Liu J, Gao J, Tu S, Xu S, Liu Y, Shang W, et al. Neuroprotective effects of Jitai tablet, a traditional Chinese medicine, on the MPTP-induced acute model of Parkinson's disease: involvement of the dopamine system. Evidence-Based Complementary Alternative Med. 2014;2014:542383.
Tu S, Gao J, Liu J, Zhang J, Huang Y, Xu S, et al. Effects of Jitai tablet, a traditional Chinese medicine, on spontaneous withdrawal symptoms and modulation of dopaminergic functions in morphine-dependent rats. Phytother Res. 2015;29(5):687–94.
Xu S, Liu Y, Li Y, Deng Y, Huang Y, Yuan J, et al. Longitudinal changes of dopamine transporters in heroin users during abstinence. Psychopharmacology. 2015;232(18):3391–401.
Jie Y, Liu XD, Han M, Rong BL, Yuan KW, Zhang GM, et al. Comparison of striatal dopamine transporter levels in chronic heroin-dependent and methamphetamine-dependent subjects. Addiction Biol. 2017;22(1):229–34.
Kita T, Wagner GC, Nakashima T. Current research on methamphetamine-induced neurotoxicity: animal models of monoamine disruption. J Pharmacological Sciences. 2003;92(3):178–95.
Xiong JG, Xiao ZX, Li J, Qin DS, Min MS, Yang JH, et al. Clinical effect of Jitai tablet combined with lofexidine in the treatment of heroin dependence. Chinese J of Drug Dependence. 2001;10(4):290–2.
Li XX, Fan HY, Sun L, Liang JC, Deng YP. Changes and the impact on immune function of opioid-dependent subjects by Jitai tablets during the withdrawal stage. Chinese J Nucl Med. 2017;38(4):531–6.
Sams Dodd F. Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia. Behav Pharmacol. 1996;7(1):3-23.
Kung MP, Liu BL, Yang YY, Billings JJ, Kung HF. A kit formulation for preparation of iodine-123-IBZM - a new Cns D-2 dopamine receptor imaging agent. J Nucl Med. 1991;32(2):339–42.
Kung MP, Stevenson DA, Plossl K, Meegalla SK, Beckwith A, Essman WD, et al. Tc-99m TRODAT-1: a novel technetium-99m complex as a dopamine transporter imaging agent. European J Nucl Med. 1997;24(4):372–80.
Ashok AH, Mizuno Y, Volkow ND, Howes OD. Association of stimulant use with dopaminergic alterations in users of cocaine, amphetamine, or methamphetamine: a systematic review and meta-analysis. Jama Psychiatry. 2017;74(5):511–9.
Qi C, Varga S, Oh SJ, Lee CJ, Lee D. Optogenetic rescue of locomotor dysfunction and dopaminergic degeneration caused by alpha-synuclein and eko genes. Experimental Neurobiology. 2017;26(2):97–103.
Budnik V, White K. Catecholamine-containing neurons in Drosophila Melanogaster: distribution and development. J Comp Neurol. 1988;268(3):400–13.
Hosp JA, Pekanovic A, Rioult-Pedotti MS, Luft AR. Dopaminergic projections from midbrain to primary motor cortex mediate motor skill learning. J Neuroscience Official J Society for Neuroscience. 2011;31(7):2481–7.
Friggi-Grelin F, Coulom H, Meller M, Gomez D, Hirsh J, Birman S. Targeted gene expression in drosophila dopaminergic cells using regulatory sequences from tyrosine hydroxylase. J Neurobiology. 2003;54(4):618–27.
Ares-Santos S, Granado N, Oliva I, O'Shea E, Martin ED, Colado MI, et al. Dopamine D-1 receptor deletion strongly reduces neurotoxic effects of methamphetamine. Neurobiol Dis. 2012;45(2):810–20.
Chen H, Wu J, Zhang J, Fujita Y, Ishima T, Iyo M, et al. Protective effects of the antioxidant sulforaphane on behavioral changes and neurotoxicity in mice after the administration of methamphetamine. Psychopharmacology. 2012;222(1):37–45.
Granado N, Lastres-Becker I, Ares-Santos S, Oliva I, Martin E, Cuadrado A, et al. Nrf2 deficiency potentiates methamphetamine-induced dopaminergic axonal damage and gliosis in the striatum. Glia. 2011;59(12):1850–63.
Liu Y, Han M, Liu X, Deng Y, Li Y, Yuan J, et al. Dopamine transporter availability in heroin-dependent subjects and controls: longitudinal changes during abstinence and the effects of Jitai tablets treatment. Psychopharmacology. 2013;230(2):235–44.
Callaghan RC, Cunningham JK, Sajeev G, Kish SJ. Incidence of Parkinson's disease among hospital patients with methamphetamine-use disorders. Mov Disord. 2010;25(14):2333–9.
Granado N, Aressantos S, Moratalla R. Methamphetamine and Parkinson's disease. Parkinsons Dis. 2013;2013(2):308052.
Todd G, Pearson-Dennett V, Wilcox RA, Chau MT, Thoirs K, Thewlis D, Vogel AP, et al. Adults with a history of illicit amphetamine use exhibit abnormal substantia nigra morphology and parkinsonism. Parkinsonism Relat Disord. 2016;25:27–32.
Schmued LC, Bowyer JF. Methamphetamine exposure can produce neuronal degeneration in mouse hippocampal remnants. Brain Res. 1997;759(1):135–40.
Hotchkiss AJ, Gibb JW. Long-term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in rat brain. J Pharmacology & Experimental Therapeutics. 1980;214(2):257–62.
More S-V, Kumar H, Kang S-M, Song S-Y, Lee K, Choi D-K. Advances in neuroprotective ingredients of medicinal herbs by using cellular and animal models of parkinson's disease. Evidence-based complementary and alternative medicine: eCAM. 2013;2013:957875.
Bisagno V, Cadet JL. Methamphetamine and MDMA neurotoxicity: biochemical and molecular mechanisms. Handbook of Neurotoxicity. 2014:347–63.
Riddle EL, Fleckenstein AE, Hanson GR. Mechanisms of methamphetamine-induced dopaminergic neurotoxicity. AAPS J. 2006;8(2):E413–8.
Halpin LE, Collins SA, Yamamoto BK. Neurotoxicity of methamphetamine and 3,4-methylenedioxymethamphetamine. Life Sci. 2014;97(1):37–44.
Tsukada H, Harada N, Nishiyama S, Ohba H, Kakiuchi T. Cholinergic neuronal modulation alters dopamine D-2 receptor availability in vivo by regulating receptor affinity induced by facilitated synaptic dopamine turnover: positron emission tomography studies with microdialysis in the conscious monkey brain. J. Neuroscience. 2000;20(18):7067–73.
Kuribara H, Uchihashi Y. Dopamine antagonists can inhibit methamphetamine sensitization, but not cocaine sensitization, when assessed by ambulatory activity in mice. J Pharm Pharmacol. 1993;45(12):1042–5.
Mohdyusof A, Veliz A, Rudberg KN, Stone MJ, Gonzalez AE, Mcdougall SA. Effects of D2 or combined D1/D2 receptor antagonism on the methamphetamine-induced one-trial and multi-trial behavioral sensitization of preweanling rats. Psychopharmacology. 2016;233(5):893–903.
Yang Z, Shao Y-c, li S-j, Qi J-l, Zhang M-j, Hao W, et al. Medication of l-tetrahydropalmatine significantly ameliorates opiate craving and increases the abstinence rate in heroin users: a pilot study. Acta Pharmacol Sin 2008; 29 (7): 781–788.
Mantsch JR, Wisniewski S, Vranjkovic O, Peters C, Becker A, Valentine A, et al. Levo-tetrahydropalmatine attenuates cocaine self-administration under a progressive-ratio schedule and cocaine discrimination in rats. Pharmacology Biochemistry Behav. 2010;97(2):310–6.
Zhao N, Chen Y, Zhu J, Wang L, Cao G, Dang Y, et al. Levo-tetrahydropalmatine attenuates the development and expression of methamphetamine-induced locomotor sensitization and the accompanying activation of Erk in the nucleus accumbens and caudate putamen in mice. Neuroscience. 2014;258:101–10.
Chu H, Jin G, Friedman E, Zhen X. Recent development in studies of tetrahydroprotoberberines: mechanism in antinociception and drug addiction. Cell Mol Neurobiology. 2008;28(4):491–9.
Rausch W-D, Radad K, Wei-Ming L, Gille G. Perspectives for ginsenosides in models of Parkinson's disease. J Ginseng Res. 2007;31(3):127–36.
Lee B, Yang CH, Hahm D-H, Lee H-J, Han S-M, Kim K-S, et al. Inhibitory effects of ginseng total saponins on behavioral sensitization and dopamine release induced by cocaine. Biological Pharmaceutical Bull. 2008;31(3):436–41.